Digital 3D Breast Tomosynthesis Versus 2D in Clinical Evaluation of High Risk Women
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02209129
Verified August 2014 by Chantal Van Ongeval, MD, Phd, Universitaire Ziekenhuizen Leuven. Recruitment status was: Recruiting
: August 5, 2014
Last Update Posted
: August 5, 2014
Universitaire Ziekenhuizen Leuven
Information provided by (Responsible Party):
Chantal Van Ongeval, MD, Phd, Universitaire Ziekenhuizen Leuven
Patients with a higher breast cancer risk (higher than 17% according to the IBIS calculation) will receive a 2D digital mammography together with a 3D tomosynthesis (so called combo tomo) of both breasts in two views in order to investigate the additional value of tomosynthesis in the diagnosis of breast cancer.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
40 Years to 90 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
women with an increased risk for breast cancer > 17% according to the IBIS calculation, and also defined by the Multidisciplinary Breast centre UZ Leuven, Belgium
more than 17% risk for breast cancer (IBIS calculation)